Search all publications

+ Advanced search

Our attorneys frequently author or co-author articles, memoranda and newsletters. Please click here if you would like to receive a copy of any of these publications.

Hong Kong Regulatory Update

September 15, 2014 | Skadden, Arps, Slate, Meagher & Flom LLP | Christopher W. Betts, Will H. Cai, Edward Lam, Alec P. Tracy

This Hong Kong regulatory update is intended to provide a brief overview of the principal Hong Kong regulatory developments in the preceding three months relevant to companies listed or proposed to be listed on The Stock Exchange of Hong Kong Limited (the HKEx) and their advisers, including HKEx announcements and rule changes, Securities and Futures Commission (SFC) decisions and updates, and both HKEx and SFC enforcement related news.

European Central Bank Publishes Final List of 'Significant Supervised Entities' in Preparation for Banking Union

September 12, 2014 | Skadden, Arps, Slate, Meagher & Flom LLP | Sven G. Mickisch, William J. Sweet, Jr., Patrick Brandt

On 4 September, the EU's European Central Bank published its final list of 'significant supervised entities' and 'less significant institutions' for the purposes of the Eurozone's single supervisory mechanism (SSM), which comes into effect in November 2014. The list constitutes a significant step in the new EU bank regulatory framework, as the SSM regulations will subject significant and non-significant entities to differing supervisory regimes.

EU Debate on Enforcement of the 'Banker Bonus Cap' Approaches End Game

September 12, 2014 | Skadden, Arps, Slate, Meagher & Flom LLP | James Anderson, Stephen G. Sims, Helena J. Derbyshire, Patrick Brandt, Gregory P. Norman

The debate over the EU's ‘Banker Bonus Cap’ is moving towards its end game as European Commission vice president, Michel Barnier, has asked the European Banking Authority for a decision this month on whether allowances paid by EU banks to key staff constitute variable compensation. This alert explains the background to the debate and suggests some possible next steps.

FTC Doubles Down in Challenge to Pharmaceutical Settlement

September 10, 2014 | Skadden, Arps, Slate, Meagher & Flom LLP | Paul M. Eckles, Karen Hoffman Lent, Sharis A. Pozen, Steven C. Sunshine

On Sept. 8, 2014, the FTC filed a federal antitrust complaint against five pharmaceutical defendants — AbbVie, Abbott Laboratories, Unimed Pharmaceuticals, Besins Healthcare and Teva Pharmaceuticals — alleging that the companies entered into an agreement to maintain a monopoly over and restrain generic competition to AndroGel, a testosterone replacement therapy product. The complaint — the first FTC reverse-payment case to be filed in the wake of the Supreme Court's seminal Actavis decision — alleges that the underlying patent infringement litigation was baseless and motivated by anti-competitive purposes (i.e., a “sham”), which marks a departure from the FTC's previous approach in these cases.